论文部分内容阅读
目的:分析人宫颈癌组织中表皮生长因子受体基因(epidermal growth factor receptor,EGFR)突变的发生和突变类型,为临床针对EGFR的靶向治疗宫颈癌提供实验依据。方法:选取86例宫颈癌患者的病理组织石蜡标样,采用酚氯仿法抽提基因组DNA,分别采用聚合酶链反应(polymerase chain reaction,PCR)技术及聚合酶链反应-限制性片段长度多态分析(restriction fragment length polymorphism-polymerase chain reaction,PCR-RLFP)检测人宫颈癌组织EGFR基因是否存在第19外显子的缺失突变及第21外显子的点突变。结果:在86例人宫颈癌组织标本中,PCR未检测到EGFR基因第19外显子的缺失突变,PCR-RLFP未检测到EGFR基因第21外显子的点突变。结论:人宫颈癌组织EGFR基因中未检测到第19外显子缺失突变和第21外显子的点突变。
OBJECTIVE: To analyze the occurrence and mutation types of epidermal growth factor receptor (EGFR) mutations in human cervical cancer tissues and provide experimental evidences for targeted targeting of EGFR in cervical cancer. Methods: Tissue paraffin samples from 86 patients with cervical cancer were collected and genomic DNA was extracted by phenol-chloroform method. The polymerase chain reaction (PCR) and polymerase chain reaction-restriction fragment length polymorphism The restriction fragment length polymorphism-polymerase chain reaction (PCR-RLFP) was used to detect the deletion mutation of exon 19 and the point mutation of exon 21 in EGFR gene of human cervical cancer. RESULTS: No mutation in exon 19 of EGFR gene was detected by PCR in 86 cases of cervical cancer, and no point mutation in exon 21 of EGFR gene was detected by PCR-RLFP. Conclusion: No mutations in exon 19 and exon 21 were detected in EGFR gene of human cervical cancer.